AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
NMC Health Plc
NMC Health Plc (LON:NMC) is the UAE based largest private healthcare services provider as well as one of the prominent fertility service providers in the world. The company serves millions of people from over the last 46 years. It is listed on London stock exchange and is considered among top 100 blue-chip companies by market cap. The company manages more than 200 healthcare facilities which consist of medical centres, hospitals, home health services, fertility clinics and long-term care facilities etc. Additionally, the companyâs doctors treat the people of Jordan, Egypt, Kenya, USA, Colombia, Seychelles, Oman, Yemen, United Kingdom, Spain, Italy, Denmark, Latvia and Sweden etc.
NMC - News Updates
On 19th December 2019, the company announced the information contained in Muddy Watersâ report, which was published on 17th December 2019, was false and misleading.
On 19th December 2019, the company announced that it purchased 100,000 shares of 10 pence each from HSBC Bank Plc on the London Stock Exchange in accordance with the $200.0 million share repurchase programme declared on 18th December 2019.
On 17th December 2019, the companyâs subsidiary NMC Health (Jersey) Limited announced the repurchase of Senior Unsecured Guaranteed Convertible Bonds due 2025 by the company. The bondholders, whose Bonds are accepted for repurchase in the offer are likely to be provided a cash consideration on 20th December 2019. The total amount of approved bonds is US $90.0 million and the U.S.$360.0 million principal amount of the bonds is expected to remain outstanding, after the Settlement Date.
On 2nd December 2019, the company got a notification from the joint chairman of the company, Mark Tompkins that on 28th November 2019, he gifted 7292 ordinary shares of 10 pence each to Sarah Tompkins which were further transferred from Sarah Tompkins to Turut Holding Ltd which is held by a family trust.
NMC â Financial Highlights
On 22nd August 2019, the company announced its six months results ended 30th June 2019.
The company reported strong performance in the core market of UAE in the first half of the year 2019.
The companyâs non-current assets increased to US$3,470.5 million at the end of first half of FY2019 as compared to US$2,480.9 million as on 31st December 2018. The current assets increased to US$1,510.8 million in the first half of FY2019 as compared to US$1,391.5 million as on 31st December 2018.
The companyâs non-current liabilities increased to US$2,404.5 million at the end of the first half of FY2019 as compared to US$1,555.6 million as on 31st December 2018. The current liabilities decreased to US$887.7 million at the end of the first half of FY2019 as compared to US$960.0 million as on 31st December 2018.
The companyâs net profit increased to US$140.1 million in the first half of FY2019 as compared to US$116.7 million in the first half of FY2018.
NMC â Share price Performance
On 20th December 2019, at 10:15 AM GMT, while writing, NMC share price was reported to be trading at GBX 1,302.50 per share on the LSE, a decrease of 15.22 per cent or GBX 234.0 per share, as compared to the previous day's closing price, which was reported to be at GBX 1,536.50 per share.
On 11th September 2019, the shares of NMC were GBX 3,059.0, which was highest and reached to GBX 1,250.50 on 20th December 2019, which was lowest in the last 52 weeks. The present share price was down by 57.42 per cent from 52-week high price whereas it was up by 4.15 per cent from the 52-week low price.
The company's market capitalisation was reportedly valued to be at GBP 3.20 billion as per the share's current market price. The stock outstanding of the NMC share has been reported to be at 208.80 million, and the free float has been said to be at 85.71 million.
The beta of the NMC share was reported to be at 0.66. It means that the company's share price movement is less volatile in its trend, as compared to the benchmark market index's movement.
Â
Puretech Health Plc
Puretech Health Plc (LON:PRTC) is a cross-disciplinary healthcare company which developing drugs for harmful diseases including lymphatic, immunological diseases, intractable cancers, CNS disorders, inflammatory and GI diseases. The companyâs lymphatic system serves as "superhighway" for cell trafficking and joins entire tissues to lymph nodes and is essential for fluid balance. The company is currently working on creating additional classes of therapeutics by taking advantage of the science of the Brain-Immune-Gut axis.
PRTC - News Updates
On 9th December 2019, the companyâs affiliate announced that it secured $84.6 million in new capital. In total, Gelesis has secured nearly $100 million to help the US launch of Plenity in the year 2019.Â
On 2nd December 2019, the company announced that its issued share capital consists of 285.3 million shares of one pence each with full voting rights as at 30th November 2019. Also, the company didnât have any stock in treasury.
PRTC - Financial Highlights
On 27th August 2019, the company announced its six months results ended 30th June 2019.
The company's total revenue decreased to $4.4 million in H1 FY2019 as compared to $4.9 million in H1 FY2018. The operating loss increased to $70.3 million in H1 FY2019 as compared to $52.3 million in H1 FY2018.
The other income increased to $115.5 million in H1 FY2019 as compared to $30.9 million in H1 FY2018. The net finance (costs)/income decreased to a loss of $34.1 million in H1 FY2019 as compared to $12.3 million in H1 FY2018.
The loss for the period decreased to a loss of $14.0 million in H1 FY2019 as compared to $15.3 million in H1 FY2018.
The company's total basic earnings/loss per share increased to $0.10 in H1 FY2019 as compared to a loss of $0.03 in H1 FY2018 whereas diluted earnings per share also increased to $0.10 in H1 FY2019 as compared to a loss of $0.03 in H1 FY2018.
The companyâs non-current assets increased to $402.2 million at the end of first half of FY2019 as compared to $182.0 million as on 31st December 2018. The current assets increased to $216.1 million at the end of first half of FY2019 as compared to $259.8 million as on 31st December 2018.
The companyâs non-current liabilities increased to $98.1 million as at the end of first half of FY2019 as compared to $9.0 million as on 31st December 2018. The current debt rose to $312.6 million at the end of the first half of FY2019 as compared to $265.8 million as on 31st December 2018.
Â
PRTC â Share price Performance
On 20th December 2019, at 08:41 AM GMT, while writing, PRTC share price was reported to be trading at GBX 284.88 per share on the LSE, a decrease of 0.04 per cent or GBX 0.12 per share, as compared to the previous day's closing price, which was reported to be at GBX 285.0 per share.
On 13th August 2019, the shares of PRTC were GBX 307.0, which was highest and reached to GBX 155.50 on 01st April 2019, which was lowest in the last 52 weeks. The present share price was down by 7.2 per cent from 52-week high price whereas it was up by 83.20 per cent from the 52-week low price.
The company's market capitalisation was reportedly valued to be at GBP 813.23 million as per the share's current market price. The stock outstanding of the PRTC share has been reported to be at 285.34 million, and the free float has been said to be at 231.61 million.
The beta of the PRTC share was reported to be at 0.81. It means that the company's share price movement is less volatile in its trend, as compared to the benchmark market index's movement.
